Wolverine Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Wolverine Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$11K	–	2481
2021 Q1	$11K	Sell	500 -1,300	-72%	-$36.2K	﹤0.01%	1858
2020 Q4	$44K	Sell	1,800 -100	-5%	-$3.31K	﹤0.01%	1352
2020 Q3	$78K	Buy	1,900 +100	+6%	+$4.59K	﹤0.01%	1179
2020 Q2	$86K	Sell	1,800 -200	-10%	-$15.4K	﹤0.01%	1124
2020 Q1	$125K	Buy	+2,000	New	+$180K	﹤0.01%	998
2018 Q1	–	Sell	-400	Closed	-$23K	–	1741
2017 Q4	$23K	Hold	400	–	–	﹤0.01%	1330
2017 Q3	$23K	Buy	+400	New	+$43.1K	﹤0.01%	1243

Wolverine Asset Management's ICPT Position: Q1 2023 in Review

Wolverine Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 17,680 shares — an estimated $306K sold.

Wolverine Asset Management first reported a position in ICPT in Q4 2017 and held it in 6 quarters. The position peaked at $2.25M in Q2 2021. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

Wolverine Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 17,680 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $306K.
Wolverine Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 6 quarters.
Wolverine Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $2.25M in Q2 2021.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.